Related Experiment Videos
Preclinical evaluation of lovastatin.
J S MacDonald1, R J Gerson, D J Kornbrust
1Department of Safety Assessment, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
The American Journal of Cardiology
|November 11, 1988
Summary
High-dose lovastatin causes toxicity in animals by over-inhibiting HMG CoA reductase. However, this animal toxicity does not predict human risk at therapeutic doses due to mechanism-based effects.
Area of Science:
- Pharmacology
- Toxicology
- Biochemistry
Background:
- Lovastatin targets HMG CoA reductase, an enzyme crucial for cholesterol synthesis.
- High-dose lovastatin administration in animals results in a wide range of toxicities.
Purpose of the Study:
- To evaluate the relevance of animal toxicity findings to human safety.
- To determine if adverse effects observed in animals predict significant risks in humans.
Main Methods:
- Review of existing toxicological data from animal studies.
- Analysis of the biochemical mechanism underlying lovastatin-induced toxicity.
- Comparison of high-dose animal effects with therapeutic human dosage levels.
Main Results:
- Animal toxicities are linked to an exaggerated pharmacological effect of lovastatin.
- Clear no-effect doses were identified for observed toxicities in animals.
- Adverse effects are mechanism-based, directly related to mevalonate synthesis inhibition.
Conclusions:
- Animal toxicity findings at high doses do not indicate significant human risk.
- Mechanism-based toxicity suggests a low likelihood of adverse effects at therapeutic human doses.
- Extensive human safety data supports the low risk profile of lovastatin in humans.